Nothing Special   »   [go: up one dir, main page]

TR201909967T4 - Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar. - Google Patents

Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar. Download PDF

Info

Publication number
TR201909967T4
TR201909967T4 TR2019/09967T TR201909967T TR201909967T4 TR 201909967 T4 TR201909967 T4 TR 201909967T4 TR 2019/09967 T TR2019/09967 T TR 2019/09967T TR 201909967 T TR201909967 T TR 201909967T TR 201909967 T4 TR201909967 T4 TR 201909967T4
Authority
TR
Turkey
Prior art keywords
light chain
histidine
genetically modified
human
human animals
Prior art date
Application number
TR2019/09967T
Other languages
English (en)
Inventor
Mcwhirter John
Macdonald Lynn
J Murphy Andrew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/030,424 external-priority patent/US20140013456A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of TR201909967T4 publication Critical patent/TR201909967T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Bir genetik olarak modifiye edilmiş insan olmayan hayvan sağlanmaktadır, burada insan olmayan hayvan, immünizasyondan sonra antijene pH'a bağlı bağlanabilen bir antikor repertuarını eksprese etmektedir. Germ hattı sekanslarında histidin modifikasyonunu içeren insan immünoglobülin hafif zincirli değişken gen segmentinin bir kısıtlı repertuarından türetilen insan immünoglobülin hafif zincirli değişken bölgeleri eksprese eden bir genetik olarak modifiye edilmiş insan olmayan hayvan sağlanmaktadır. İmmünoglobulin hafif zincirli nükleotid sekanslarına dahil edilen histidin kodonları ile kodlanan histidin kalıntılarını içeren antikorları eksprese eden insan olmayan hayvanların oluşturulmasına yönelik yöntemler sağlanmaktadır.
TR2019/09967T 2013-09-18 2014-09-18 Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar. TR201909967T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/030,424 US20140013456A1 (en) 2012-03-16 2013-09-18 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same

Publications (1)

Publication Number Publication Date
TR201909967T4 true TR201909967T4 (tr) 2019-07-22

Family

ID=51663490

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09967T TR201909967T4 (tr) 2013-09-18 2014-09-18 Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar.

Country Status (25)

Country Link
EP (2) EP3549437B1 (tr)
JP (3) JP6621750B2 (tr)
KR (2) KR102150414B1 (tr)
CN (2) CN111019953A (tr)
AU (2) AU2014323527B2 (tr)
BR (1) BR112016005912A2 (tr)
CA (1) CA2922892C (tr)
CY (1) CY1121798T1 (tr)
DK (1) DK3046412T3 (tr)
ES (2) ES2738679T3 (tr)
HK (1) HK1225913A1 (tr)
HR (1) HRP20191233T1 (tr)
HU (1) HUE044747T2 (tr)
IL (2) IL244226B (tr)
LT (1) LT3046412T (tr)
MX (1) MX362904B (tr)
MY (1) MY191512A (tr)
PL (1) PL3046412T3 (tr)
PT (1) PT3046412T (tr)
RS (1) RS59003B1 (tr)
RU (2) RU2694728C2 (tr)
SG (2) SG10201810825YA (tr)
SI (1) SI3046412T1 (tr)
TR (1) TR201909967T4 (tr)
WO (1) WO2015042250A1 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
RU2739792C1 (ru) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
CN104736706B (zh) 2012-08-24 2021-10-19 中外制药株式会社 FcγRIIb特异性Fc区变体
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
US20220090125A1 (en) * 2018-12-21 2022-03-24 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
US20230071042A1 (en) * 2019-12-18 2023-03-09 Bristo-Myers Squibb Company Bcr transgenic mice with a common leader sequence
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CN114568343B (zh) * 2022-03-11 2023-04-07 成都合拓创展生物科技有限公司 制备眼病模型的头具及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MY147468A (en) 2006-06-02 2012-12-14 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP4954326B2 (ja) * 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
DK2975051T3 (da) 2009-06-26 2021-04-26 Regeneron Pharma Let-at-isolere bispecifikke antistoffer med nativt immunoglobulinformat
ES2658622T3 (es) 2009-07-16 2018-03-12 Wageningen Universiteit Regulación de la deficiencia de zinc y tolerancia en plantas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
KR20120118045A (ko) * 2010-01-21 2012-10-25 옥시레인 유케이 리미티드 효모 세포 표면상에 폴리펩티드를 디스플레이하기 위한 방법들 및 조성물들
RS54367B2 (sr) 2010-02-08 2021-08-31 Regeneron Pharma Miš sa zajedničkim lakim lancem
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PE20130393A1 (es) * 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
CN103068993B (zh) * 2010-06-22 2016-01-06 瑞泽恩制药公司 杂交轻链小鼠
CN103237809B (zh) * 2010-11-19 2016-09-07 莫佛塞斯公司 一个集合及其使用方法
EP2762564B1 (en) * 2011-09-30 2020-09-16 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
US20140013456A1 (en) * 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR101764800B1 (ko) * 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물

Also Published As

Publication number Publication date
AU2021200228A1 (en) 2021-03-18
HK1225913A1 (zh) 2017-09-22
DK3046412T3 (da) 2019-07-15
AU2014323527B2 (en) 2020-10-15
PT3046412T (pt) 2019-07-16
IL244226A0 (en) 2016-04-21
WO2015042250A4 (en) 2015-05-28
HUE044747T2 (hu) 2019-11-28
MY191512A (en) 2022-06-28
RS59003B1 (sr) 2019-08-30
SG11201601272YA (en) 2016-03-30
ES2738679T3 (es) 2020-01-24
IL264358A (en) 2019-02-28
RU2694728C2 (ru) 2019-07-16
CY1121798T1 (el) 2020-07-31
KR20200103882A (ko) 2020-09-02
EP3549437A1 (en) 2019-10-09
HRP20191233T1 (hr) 2019-10-18
EP3549437B1 (en) 2023-10-25
RU2016114306A3 (tr) 2018-04-26
EP3046412A1 (en) 2016-07-27
EP3046412B1 (en) 2019-04-10
CN105722387B (zh) 2020-01-17
KR20160049018A (ko) 2016-05-04
JP6621750B2 (ja) 2019-12-18
ES2962489T3 (es) 2024-03-19
JP2016533768A (ja) 2016-11-04
JP2019068850A (ja) 2019-05-09
PL3046412T3 (pl) 2019-11-29
MX2016003638A (es) 2016-07-21
CN111019953A (zh) 2020-04-17
RU2019121863A (ru) 2019-08-29
SG10201810825YA (en) 2019-01-30
WO2015042250A9 (en) 2016-04-28
JP2020078350A (ja) 2020-05-28
IL244226B (en) 2019-02-28
WO2015042250A1 (en) 2015-03-26
LT3046412T (lt) 2019-07-25
CA2922892C (en) 2022-06-14
EP3549437C0 (en) 2023-10-25
AU2014323527A1 (en) 2016-04-07
SI3046412T1 (sl) 2019-08-30
RU2016114306A (ru) 2017-10-23
KR102150414B1 (ko) 2020-09-02
CN105722387A (zh) 2016-06-29
BR112016005912A2 (pt) 2017-09-26
MX362904B (es) 2019-02-25
CA2922892A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
TR201909967T4 (tr) Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar.
CY1117606T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1120599T1 (el) Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα τρωκτικα για τη δημιουργια αυτων
IN2014DN08163A (tr)
CY1119657T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
MX2021000484A (es) Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.
WO2013041845A3 (en) Animals, repertoires & methods for the production of human antibodies
MX2015012540A (es) Ratón de cadena ligera común.
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
MX2024004496A (es) Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
TR201901668T4 (tr) Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
MX2011007660A (es) Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
IN2014CN04183A (tr)
ECSP20011317A (es) ANTICUERPOS CONTRA MAdCAM